McDermott Will & Emery advised STADA Arzneimittel AG on the deal. STADA Arzneimittel AG announced it has entered into an exclusive commercialization and license agreement with...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery and CK Legal advised Ryvu Therapeutics S.A., while Osborne Clarke and CMS Poland advised BioNTech on the deal. Ryvu Therapeutics S.A., a...
You must be a Standard 1 Year member to access this content.
Noerr advised AUCTUS, while Freshfields Bruckhaus Deringer advised AmerisourceBergen Corporation. McDermott Will & Emery, Buntscheck and Emnay advised Auctus Capital Partners/Pharmalex. AmerisourceBergen Corporation (NYSE: ABC) signed a...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Ryvu Therapeutics in the transaction. Ryvu Therapeutics S.A. entered into an exclusive license agreement with Exelixis. The cooperation is focused on the...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery has advised PAION AG on a license agreement with Cristália Produtos Quimicos Farmaceuticos Ltda. PAION grants Cristália an exclusive license for the...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented REGENXBIO in the transaction. REGENXBIO closed its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised STADA Arzneimittel on the deal. STADA Arzneimittel AG closed a license agreement to register and commercialize a novel specialty drug candidate...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised neuroloop GmbH on the deal, while McDermott Will & Emery advised Merck KGaA. Neuroloop GmbH, part of B. Braun Group, announced a...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery acted as Transaction Counsel for the issuer, its main shareholder Paragon Partners as well as the Joint Bookrunners Hauck & Aufhäuser and...
You must be a Standard 1 Year member to access this content.
